PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
37/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePBH / S&P -20.25% / 15.20% |
LosePBH / S&P -1.36% / 15.00% |
LosePBH / S&P -16.39% / 50.40% |
| 2026-Q11/3 |
WinPBH / S&P -3.92% / -4.33% |
LosePBH / S&P -4.31% / 11.30% |
LosePBH / S&P -9.07% / 27.70% |
| 2025-Q40/3 |
LosePBH / S&P -1.14% / 2.65% |
LosePBH / S&P -1.31% / 9.00% |
LosePBH / S&P -11.24% / 13.40% |
| 2025-Q30/3 |
LosePBH / S&P -21.85% / 8.12% |
LosePBH / S&P -0.02% / 4.61% |
LosePBH / S&P -1.70% / 13.45% |
| 2025-Q20/3 |
LosePBH / S&P -7.12% / 10.94% |
LosePBH / S&P 0.63% / 4.83% |
LosePBH / S&P 4.40% / 10.63% |
| 2025-Q11/3 |
WinPBH / S&P 10.09% / -4.27% |
LosePBH / S&P 1.10% / 4.98% |
LosePBH / S&P 3.12% / 10.57% |
| 2024-Q41/3 |
WinPBH / S&P 8.31% / 2.41% |
LosePBH / S&P -1.41% / 5.25% |
LosePBH / S&P -366.88% / 6.15% |
| 2024-Q30/3 |
LosePBH / S&P 4.72% / 5.89% |
LosePBH / S&P -1.45% / 5.89% |
LosePBH / S&P -353.70% / 6.11% |
| 2024-Q20/3 |
LosePBH / S&P -5.11% / 4.28% |
LosePBH / S&P -1.49% / 5.38% |
LosePBH / S&P -344.91% / 5.12% |
| 2024-Q11/3 |
WinPBH / S&P 18.52% / 10.56% |
LosePBH / S&P -0.21% / 5.71% |
LosePBH / S&P -354.27% / 5.59% |
| 2023-Q40/3 |
LosePBH / S&P 7.05% / 11.69% |
LosePBH / S&P 2.29% / 6.81% |
LosePBH / S&P -138.37% / 7.78% |
| 2023-Q30/3 |
LosePBH / S&P -3.77% / -3.27% |
LosePBH / S&P 1.74% / 7.52% |
LosePBH / S&P -139.32% / -5.03% |
| 2023-Q20/3 |
LosePBH / S&P -5.11% / 8.74% |
LosePBH / S&P 3.22% / 9.50% |
LosePBH / S&P -141.85% / -8.57% |
| 2023-Q10/3 |
LosePBH / S&P 0.05% / 7.50% |
LosePBH / S&P 3.76% / 10.77% |
LosePBH / S&P -140.59% / -15.69% |
| 2022-Q42/3 |
WinPBH / S&P 25.63% / 7.56% |
LosePBH / S&P 4.84% / 11.88% |
WinPBH / S&P 12.10% / -17.99% |
| 2022-Q31/3 |
LosePBH / S&P -15.26% / -4.88% |
LosePBH / S&P 8.39% / 13.47% |
WinPBH / S&P 16.38% / -1.41% |
| 2022-Q22/3 |
WinPBH / S&P 11.07% / -16.10% |
LosePBH / S&P 11.34% / 13.71% |
WinPBH / S&P 13.03% / 11.04% |
| 2022-Q10/3 |
LosePBH / S&P -12.71% / -4.60% |
LosePBH / S&P 15.21% / 15.97% |
LosePBH / S&P 24.31% / 42.23% |
| 2021-Q40/3 |
LosePBH / S&P 8.09% / 11.03% |
LosePBH / S&P 10.53% / 15.00% |
LosePBH / S&P 13.41% / 96.40% |
| 2021-Q31/3 |
WinPBH / S&P 7.70% / 0.58% |
LosePBH / S&P 6.50% / 10.77% |
LosePBH / S&P 9.94% / 69.42% |
| 2021-Q21/3 |
WinPBH / S&P 18.19% / 8.55% |
LosePBH / S&P 2.39% / 6.58% |
LosePBH / S&P 18.06% / 51.81% |
| 2021-Q12/3 |
WinPBH / S&P 26.41% / 6.17% |
LosePBH / S&P -2.04% / -1.06% |
WinPBH / S&P 16.91% / 7.39% |
| 2020-Q41/3 |
LosePBH / S&P -4.26% / 12.15% |
WinPBH / S&P 0.42% / -3.72% |
LosePBH / S&P -637.70% / -33.42% |
| 2020-Q31/3 |
LosePBH / S&P -3.04% / 8.93% |
WinPBH / S&P 0.73% / -2.04% |
LosePBH / S&P -611.11% / -27.10% |
| 2020-Q21/3 |
LosePBH / S&P 2.40% / 20.54% |
WinPBH / S&P 0.66% / -0.46% |
LosePBH / S&P -533.33% / -27.11% |
| 2020-Q11/3 |
WinPBH / S&P -9.43% / -19.60% |
LosePBH / S&P -1.31% / 3.47% |
LosePBH / S&P -502.90% / -14.75% |
| 2019-Q41/3 |
WinPBH / S&P 16.75% / 9.07% |
LosePBH / S&P -3.83% / 5.36% |
LosePBH / S&P -149.59% / 2.99% |
| 2019-Q31/3 |
WinPBH / S&P 9.50% / 1.70% |
LosePBH / S&P -6.59% / 5.02% |
LosePBH / S&P -109.87% / 0.21% |
| 2019-Q21/3 |
WinPBH / S&P 5.92% / 4.30% |
LosePBH / S&P -8.15% / 6.64% |
LosePBH / S&P -110.85% / 8.65% |
| 2019-Q10/3 |
LosePBH / S&P -3.14% / 13.65% |
LosePBH / S&P -6.28% / 8.12% |
LosePBH / S&P -110.88% / 14.29% |
| 2018-Q40/3 |
LosePBH / S&P -18.50% / -13.52% |
LosePBH / S&P -3.43% / 9.05% |
LosePBH / S&P -83.13% / 18.23% |
| 2018-Q31/3 |
LosePBH / S&P -1.28% / 7.71% |
LosePBH / S&P 4.93% / 10.21% |
WinPBH / S&P 219.00% / 19.06% |
| 2018-Q23/3 |
WinPBH / S&P 13.82% / 3.43% |
WinPBH / S&P 11.79% / 9.03% |
WinPBH / S&P 213.30% / 14.46% |
| 2018-Q12/3 |
LosePBH / S&P -24.07% / -0.76% |
WinPBH / S&P 18.04% / 7.68% |
WinPBH / S&P 387.69% / 12.46% |
| 2017-Q42/3 |
LosePBH / S&P -11.34% / 6.64% |
WinPBH / S&P 20.80% / 7.03% |
WinPBH / S&P 440.00% / 13.82% |
| 2017-Q32/3 |
LosePBH / S&P -5.15% / 4.48% |
WinPBH / S&P 16.74% / 5.68% |
WinPBH / S&P 55.04% / 17.57% |
| 2017-Q22/3 |
LosePBH / S&P -4.95% / 3.09% |
WinPBH / S&P 12.79% / 4.83% |
WinPBH / S&P 57.36% / 17.74% |
| 2017-Q12/3 |
WinPBH / S&P 6.64% / 6.07% |
WinPBH / S&P 9.40% / 3.67% |
LosePBH / S&P -30.85% / 13.32% |
| 2016-Q42/3 |
WinPBH / S&P 7.93% / 3.82% |
WinPBH / S&P 7.71% / 2.09% |
LosePBH / S&P -34.78% / 7.05% |
| 2016-Q31/3 |
LosePBH / S&P -12.87% / 3.85% |
WinPBH / S&P 5.96% / 0.20% |
LosePBH / S&P -33.51% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PBH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -24.74% | 20.78% |
| Annualized return | -24.74% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PBH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -10.78% | 83.14% |
| Annualized return | -2.26% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | PBH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 7.36% | 319.30% |
| Annualized return | 0.71% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |